EA200600209A1 - ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ - Google Patents

ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ

Info

Publication number
EA200600209A1
EA200600209A1 EA200600209A EA200600209A EA200600209A1 EA 200600209 A1 EA200600209 A1 EA 200600209A1 EA 200600209 A EA200600209 A EA 200600209A EA 200600209 A EA200600209 A EA 200600209A EA 200600209 A1 EA200600209 A1 EA 200600209A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrrolo
pyrazole
derivatives
activated
kinase inhibitors
Prior art date
Application number
EA200600209A
Other languages
English (en)
Other versions
EA009462B1 (ru
Inventor
Даниеле Фанчелли
Барбара Форте
Юрген Молль
Марио Варази
Паола Вианелло
Original Assignee
Фармация Италия С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Италия С.П.А. filed Critical Фармация Италия С.П.А.
Publication of EA200600209A1 publication Critical patent/EA200600209A1/ru
Publication of EA009462B1 publication Critical patent/EA009462B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Раскрыты производные пирроло[3,4-с]пиразола формулы (I) и их фармацевтически приемлемые соли, определенные в описании, способ их получения и фармацевтические композиции, содержащие данные соединения; соединения по изобретению могут применяться в терапии для лечения заболеваний, подобных раку, связанных с дисрегуляцией активности протеинкиназы.
EA200600209A 2003-07-09 2004-07-08 Производные пирроло[3.4-с]пиразола, обладающие активностью как ингибиторы киназы EA009462B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09
PCT/EP2004/007515 WO2005005427A1 (en) 2003-07-09 2004-07-08 PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
EA200600209A1 true EA200600209A1 (ru) 2006-06-30
EA009462B1 EA009462B1 (ru) 2007-12-28

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600209A EA009462B1 (ru) 2003-07-09 2004-07-08 Производные пирроло[3.4-с]пиразола, обладающие активностью как ингибиторы киназы

Country Status (42)

Country Link
US (2) US7141568B2 (ru)
EP (1) EP1644376B1 (ru)
JP (1) JP4728232B2 (ru)
KR (1) KR101075711B1 (ru)
CN (1) CN100564380C (ru)
AP (1) AP2214A (ru)
AR (1) AR050045A1 (ru)
AT (1) ATE480540T1 (ru)
AU (1) AU2004255347B2 (ru)
BR (1) BRPI0411868B8 (ru)
CA (1) CA2531759C (ru)
CR (1) CR8171A (ru)
CY (1) CY1110832T1 (ru)
DE (1) DE602004029045D1 (ru)
DK (1) DK1644376T3 (ru)
DO (1) DOP2004000949A (ru)
EA (1) EA009462B1 (ru)
EC (1) ECSP056246A (ru)
ES (1) ES2349780T3 (ru)
GE (1) GEP20084395B (ru)
GT (2) GT200400133A (ru)
HK (1) HK1089769A1 (ru)
HN (1) HN2004000232A (ru)
IL (1) IL172923A (ru)
IS (1) IS2843B (ru)
MA (1) MA28064A1 (ru)
ME (1) MEP51908A (ru)
MX (1) MXPA06000362A (ru)
MY (1) MY139072A (ru)
NO (1) NO332361B1 (ru)
NZ (1) NZ544514A (ru)
PA (1) PA8606201A1 (ru)
PE (1) PE20050325A1 (ru)
PL (1) PL1644376T3 (ru)
PT (1) PT1644376E (ru)
RS (2) RS52155B (ru)
SI (1) SI1644376T1 (ru)
TN (1) TNSN06009A1 (ru)
TW (1) TWI343382B (ru)
UA (1) UA81682C2 (ru)
WO (1) WO2005005427A1 (ru)
ZA (1) ZA200600095B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
JP2008510734A (ja) * 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) * 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2008052931A1 (en) * 2006-11-03 2008-05-08 Nerviano Medical Sciences S.R.L. A method of administering an antitumor compound
AR071780A1 (es) 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
US20110129467A1 (en) * 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
CN102105147B (zh) * 2008-07-24 2013-07-03 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
US20100183601A1 (en) 2008-12-22 2010-07-22 Millennium Pharmaceuticals, Inc. Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies
CA2858958C (en) 2011-12-12 2016-10-04 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US9394305B2 (en) 2014-06-23 2016-07-19 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
AU2016281225B2 (en) 2015-06-15 2020-10-15 Ube Corporation Substituted dihydropyrrolopyrazole derivative
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024006424A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Kras g12c inhibitor for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
CA2430151A1 (en) 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
EP1379524A2 (en) 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Chromane derivatives, process for their preparation and their use as antitumor agents
EA007430B1 (ru) 2001-09-26 2006-10-27 Фармация Италия С.П.А. Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
MEP51908A (en) 2011-05-10
CN100564380C (zh) 2009-12-02
SI1644376T1 (sl) 2010-11-30
CR8171A (es) 2006-08-09
EA009462B1 (ru) 2007-12-28
GT200400133AA (es) 2007-07-10
HK1089769A1 (en) 2006-12-08
IS8192A (is) 2005-12-22
ZA200600095B (en) 2007-01-31
BRPI0411868B8 (pt) 2021-05-25
AP2214A (en) 2011-03-04
ES2349780T3 (es) 2011-01-11
MA28064A1 (fr) 2006-08-01
KR101075711B1 (ko) 2011-10-21
CA2531759A1 (en) 2005-01-20
IS2843B (is) 2013-08-15
US20060276471A1 (en) 2006-12-07
ECSP056246A (es) 2006-04-19
MY139072A (en) 2009-08-28
ATE480540T1 (de) 2010-09-15
NZ544514A (en) 2009-07-31
US20050032839A1 (en) 2005-02-10
AR050045A1 (es) 2006-09-27
RS52155B (en) 2012-08-31
JP4728232B2 (ja) 2011-07-20
KR20060033001A (ko) 2006-04-18
IL172923A (en) 2011-09-27
AP2006003480A0 (en) 2006-02-28
AU2004255347A1 (en) 2005-01-20
TNSN06009A1 (fr) 2007-10-03
TW200510385A (en) 2005-03-16
PT1644376E (pt) 2010-09-24
US7141568B2 (en) 2006-11-28
IL172923A0 (en) 2006-06-11
EP1644376A1 (en) 2006-04-12
BRPI0411868A (pt) 2006-08-08
PA8606201A1 (es) 2005-08-04
PL1644376T3 (pl) 2011-03-31
GT200400133A (es) 2005-04-18
AU2004255347B2 (en) 2010-04-08
EP1644376B1 (en) 2010-09-08
WO2005005427A1 (en) 2005-01-20
UA81682C2 (en) 2008-01-25
PE20050325A1 (es) 2005-05-17
TWI343382B (en) 2011-06-11
GEP20084395B (en) 2008-06-10
RS20060004A (en) 2008-06-05
CN1820009A (zh) 2006-08-16
DE602004029045D1 (de) 2010-10-21
HN2004000232A (es) 2011-01-17
MXPA06000362A (es) 2006-03-28
CY1110832T1 (el) 2015-06-10
CA2531759C (en) 2013-04-02
JP2009513525A (ja) 2009-04-02
DOP2004000949A (es) 2005-01-15
US7582628B2 (en) 2009-09-01
NO20060113L (no) 2006-04-05
DK1644376T3 (da) 2011-01-03
NO332361B1 (no) 2012-09-03
BRPI0411868B1 (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
MY143206A (en) 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
ECSP066767A (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
UY28409A1 (es) Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa
CU20060152A7 (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU